Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Pharma/Biotech Companies - In the News
>
Alnylam makes case for lumasiran in infants ahead of FDA ruling
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="cafead, post: 6469142, member: 1"]via Alnylam has shared data from a phase 3 trial of its near-approval kidney disease drug lumasiran in children as young as three months. The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.</p><p><br /></p><p><a href="https://bit.ly/3ojSpNc" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://bit.ly/3ojSpNc" rel="nofollow">article source</a>[/QUOTE]</p><p><br /></p>
[QUOTE="cafead, post: 6469142, member: 1"]via Alnylam has shared data from a phase 3 trial of its near-approval kidney disease drug lumasiran in children as young as three months. The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population. [url="https://bit.ly/3ojSpNc"]article source[/url][/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Pharma/Biotech Companies - In the News
>
Alnylam makes case for lumasiran in infants ahead of FDA ruling
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Pharma/Biotech Companies - In the News
>
Alnylam makes case for lumasiran in infants ahead of FDA ruling
>